145 related articles for article (PubMed ID: 37647139)
1. Adherence to Hormonal Therapies in Prostate Cancer.
Hafron J; Sangha P; Kung T; Pruett J
Urol Pract; 2023 Nov; 10(6):540-546. PubMed ID: 37647139
[TBL] [Abstract][Full Text] [Related]
2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
4. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
5. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
Tatenuma T; Miyamoto H
Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910
[TBL] [Abstract][Full Text] [Related]
6. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T
Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587
[TBL] [Abstract][Full Text] [Related]
7. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
8. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
9. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
10. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
11. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
Adekunle OA; Seoane-Vazquez E; Brown LM
J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
[TBL] [Abstract][Full Text] [Related]
15. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
[TBL] [Abstract][Full Text] [Related]
16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
[TBL] [Abstract][Full Text] [Related]
18. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
19. [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
Vojinov S; Levakov I; Jeremić D; Zivojinov S; Marusić G
Vojnosanit Pregl; 2011 Apr; 68(4):321-6. PubMed ID: 21630520
[TBL] [Abstract][Full Text] [Related]
20. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]